A trial of L-Deprenyl for the treatment of neuroleptic-induced parkinsonism

A. Rapoport*, D. Stein, M. Schwartz, J. Levin, S. Stier, A. Elizur, J. M. Rabey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


This study examined the potential of L-Deprenyl, a selective monoamine oxidase-B (MAO-B) inhibitor, for the treatment of neuroleptic-induced parkinsonism (NIP). Thirty-one consecutive schizophrenic or schizophreniform patients were treated with haloperidol in a flexible dose design. Nineteen of them developed NIP and were administered adjunctive L-Deprenyl 10 mg/d for six weeks in an open fixed-dose design. One patient had to be withdrawn from the study because of exacerbation of the NIP. Severity of NIP was mild to moderate throughout the whole study period in all other cases. Five patients were considered to require biperiden 2-4 mg/d in addition to L-Deprenyl after two weeks of treatment, although they did not differ from the other 13 patients in any of the variables studied. A significant improvement in NIP was found in both groups of patients, with no psychotic exacerbation or a change in the dosage of haloperidol. These findings suggest that selective MAO-B inhibitors may be effective in some patients with mild to moderate NIP.

Original languageEnglish
Pages (from-to)911-918
Number of pages8
JournalJournal of Neural Transmission
Issue number9-10
StatePublished - 1999
Externally publishedYes


  • L-Deprenyl
  • MAO-B inhibitors
  • Neuroleptic-induced parkinsonism
  • Schizophrenia


Dive into the research topics of 'A trial of L-Deprenyl for the treatment of neuroleptic-induced parkinsonism'. Together they form a unique fingerprint.

Cite this